| Reference cohort | TIA study cohort | p-value | ||
---|---|---|---|---|---|
One year before index hospitalization (A) | One year before index hospitalization (B) | One year after index discharge (C) | (A vs. B) | (B vs. C) | |
Drugs | |||||
 Blood pressure-lowering agents | 4,544 (58.4%) | 5,255 (67.6%) | 5,819 (74.8%) | <0.0001 | <0.0001 |
 Lipid-lowering agents | 1,358 (17.5%) | 1,446 (18.6%) | 2,651 (34.1%) | 0.0612 | <0.0001 |
 Antiplatelet drugs | 2,162 (27.8%) | 2,754 (35.4%) | 5,926 (76.2%) | <0.0001 | <0.0001 |
 Oral anticoagulants | 421 (5.4%) | 499 (6.4%) | 997 (12.8%) | 0.0077 | <0.0001 |
 Antiarrhythmics | 345 (4.4%) | 416 (5.3%) | 535 (6.9%) | 0.0082 | <0.0001 |
 Antidiabetics | 867 (11.1%) | 1,233 (15.9%) | 1,300 (16.7%) | 0.0192 | 0.0002 |
 None of the previous | 2,720 (35.0%) | 1,958 (25.2%) | 667 (8.6%) | <0.0001 | <0.0001 |
Diagnostic procedures | |||||
 Cardiac doppler ultrasonography | 690 (8.9%) | 845 (10.9%) | 1,075 (13.8%) | <0.0001 | <0.0001 |
 Carotid doppler ultrasonography | 633 (8.1%) | 759 (9.8%) | 1,172 (15.1%) | 0.0004 | <0.0001 |
 Neuroimaging or cerebral angiography | 156 (2.0%) | 277 (3.6%) | 769 (9.9%) | <0.0001 | <0.0001 |
 Electrocardiogram | 1,739 (22.4%) | 2,396 (30.8%) | 2,525 (32.5%) | <0.0001 | 0.0119 |
 None of the previous | 5,465 (70.3%) | 4,744 (61.0%) | 3,863 (49.7%) | <0.0001 | <0.0001 |
Laboratory tests | |||||
 Total cholesterol | 3,622 (46.6%) | 3,827 (49.2%) | 3,698 (47.6%) | 0.0007 | 0.0149 |
 Glycosylated haemoglobin, Type A1C | 1,070 (13.8%) | 1,339 (17.2%) | 1,434 (18.4%) | <0.0001 | 0.0024 |
 None of the previous | 3,958 (50.9%) | 3,720 (47.8%) | 3,775 (48.5%) | <0.0001 | 0.1947 |
 None of the previous drugs, diagnostic procedures, nor laboratory tests | 1,652 (21.2%) | 1,104 (14.2%) | 388 (5.0%) | <0.0001 | <0.0001 |